

Press release

STADA recognized as "Company of the year, EMEA" for the second year in a row

Bad Vilbel, November 6, 2019 – This year, at the sixth Global Generics & Biosimilars Awards, STADA Arzneimittel AG was once again able to impress the independent jury and, as was the case in the previous year, was the winner in the category "Company of the year, EMEA".

The fact that STADA has now won the award for the second year in a row confirms that the Group is on its way to becoming a major player in the European healthcare sector.

The Global Generics & Biosimilars Awards are presented annually by the international industry magazine Generics Bulletin in cooperation with IQVIA.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The Group is pursuing a two pillar strategy focused on generics, including specialty pharmaceuticals, and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.



Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de Or visit us on the Internet at www.stada.com/investor-relations

Executive Board: Peter Goldschmidt (CEO) / Mark Keatley / Miguel Pagan Fernandez Supervisory Board Chairman: Dr. Günter von Au